A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Official Title

A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma

Summary:

This is a global, Phase 1/2, multicentre, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 dose (RP2D), preliminary efficacy, and safety of selinexor in combination with SoC therapy for newly diagnosed glioblastoma multiforme (GBM) (nGBM) or recurrent GBM (rGBM). The study will independently evaluate 3 different combination regimens in 3 treatment arms in participants with nGBM O6-methylguanine-DNA-methyltransferase [MGMT] promotor unmethylated [uMGMT] disease in Arm A, MGMT methylated [mMGMT]) in Arm B, and participants with rGBM regardless of MGMT status in Arm C. The second phase of the study will compare selinexor+SoC treatments versus SoC treatment alone in the three treatment Arms.

Trial Description

Primary Outcome:

  • Phase 1: Maximum Tolerated Dose Per Arm: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
  • Phase 1: Recommended Phase 2 Dose Per Arm
  • Phase 1: Number of Participants with Adverse Events (AEs) with Grade Greater Than or Equal to (>=) 3, Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
  • Phase 2: Progression-free Survival (PFS) in Newly Diagnosed Glioblastoma Multiforme Participants in Arms A and B
  • Phase 2: Overall Survival (OS) in Recurrent Glioblastoma Multiforme Participants in Arm C
Secondary Outcome:
  • Phase 1: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C
  • Phase 1: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology Criteria in Arm C
  • Phase 1: Duration of Response (DOR) in Arm C
  • Phase 1: Time-to-progression (TTP) Per Arm Independently
  • Phase 1: Progression Free Survival Per Arm Independently
  • Phase 1: Overall Survival Per Arm Independently
  • Phase 1: Maximum Plasma Concentration (Cmax) of Selinexor in Plasma When Administered With Radiation Therapy, Temozolomide, and/or Lomustine
  • Phase 1: Area Under the Concentration-time Curve (AUC) of Selinexor in Plasma When Administered With Radiation Therapy, Temozolomide, and/or Lomustine
  • Phase 1: Apparent Clearance (CL) of Selinexor in Plasma When Administered With Radiation Therapy, Temozolomide, and/or Lomustine
  • Phase 2: Overall Survival for Newly Diagnosed Glioblastoma Multiforme Participants in Arms A and B
  • Phase 2: Progression Free Survival Per Modified Response Assessment in Neuro-Oncology Criteria in Participants With Recurrent Glioblastoma Multiforme Per Independent Review Committee Assessment in Arm C
  • Phase 2: Progression Free Survival Per Modified Response Assessment in Neuro-Oncology Criteria in Arms A, B, and C: Per Investigator Assessment
  • Phase 2: Rate of Progression Free Survival at 6-month (PFS6)
  • Phase 2: Overall Response Rate Per Independent Review Committee and Investigator Assessment in Arm C
  • Phase 2: Disease Control Rate Per Independent Review Committee and Investigator Assessment in Arm C
  • Phase 2: Duration of Response Per Independent Review Committee and Investigator Assessment in Arm C
  • Phase 2: 1 and 2-year Overall Survival Rate of Participants in Arms A, B, and C
  • Phase 2: Number of Participants With Abnormalities Related to Vital Signs, Clinical Laboratory Values, and Physical Examinations
  • Phase 2: Number of Participants With Any Treatment-emergent Adverse Events (AEs) (TEAEs) by Severity Grade ≥3, Serious Adverse event (SAEs), and AEs Leading to Treatment Discontinuation

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society